Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Published:2018-10 Issue:10 Volume:19 Page:1315-1327
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Ascierto Paolo A,Gogas Helen J,Arance Ana,Mandala Mario,Liszkay Gabriella,Garbe Claus,Schadendorf Dirk,Krajsova Ivana,Gutzmer Ralf,Chiarion Sileni Vanna,Dutriaux Caroline,de Groot Jan Willem B,Yamazaki Naoya,Loquai Carmen,Moutouh-de Parseval Laure A,Pickard Michael D,Sandor Victor,Robert Caroline,Flaherty Keith T

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas;Krauthammer;Nat Genet,2015

2. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

3. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition;Zimmer;J Clin Oncol,2012

4. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N Engl J Med,2010

5. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma;Bollag;Nature,2010

Cited by 476 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma;Cancer Treatment Reviews;2024-09

3. Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib;Cancers;2024-08-23

4. Cutaneous Melanoma: An Overview of Physiological and Therapeutic Aspects and Biotechnological Use of Serine Protease Inhibitors;Molecules;2024-08-16

5. Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications;Heliyon;2024-08